PH12016500739B1 - Inhibitors of the fibrolast growth factor receptor - Google Patents
Inhibitors of the fibrolast growth factor receptorInfo
- Publication number
- PH12016500739B1 PH12016500739B1 PH1/2016/500739A PH12016500739A PH12016500739B1 PH 12016500739 B1 PH12016500739 B1 PH 12016500739B1 PH 12016500739 A PH12016500739 A PH 12016500739A PH 12016500739 B1 PH12016500739 B1 PH 12016500739B1
- Authority
- PH
- Philippines
- Prior art keywords
- inhibitors
- growth factor
- factor receptor
- fibrolast
- fibrolast growth
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895472P | 2013-10-25 | 2013-10-25 | |
| US201461927782P | 2014-01-15 | 2014-01-15 | |
| PCT/US2014/061974 WO2015061572A1 (en) | 2013-10-25 | 2014-10-23 | Inhibitors of the fibroblast growth factor receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12016500739A1 PH12016500739A1 (en) | 2016-05-30 |
| PH12016500739B1 true PH12016500739B1 (en) | 2022-04-29 |
Family
ID=51947473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2016/500739A PH12016500739B1 (en) | 2013-10-25 | 2014-10-23 | Inhibitors of the fibrolast growth factor receptor |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US9434700B2 (OSRAM) |
| EP (2) | EP3060560A1 (OSRAM) |
| JP (2) | JP6458023B2 (OSRAM) |
| KR (1) | KR102405452B1 (OSRAM) |
| CN (2) | CN110028491B (OSRAM) |
| AU (1) | AU2014339972B9 (OSRAM) |
| BR (1) | BR112016008849B8 (OSRAM) |
| CA (1) | CA2928042C (OSRAM) |
| CY (1) | CY1125393T1 (OSRAM) |
| DK (1) | DK3395814T3 (OSRAM) |
| ES (1) | ES2924111T3 (OSRAM) |
| HR (1) | HRP20220840T1 (OSRAM) |
| HU (1) | HUE059037T2 (OSRAM) |
| IL (1) | IL244738B (OSRAM) |
| LT (1) | LT3395814T (OSRAM) |
| MX (1) | MX2016005297A (OSRAM) |
| PH (1) | PH12016500739B1 (OSRAM) |
| PL (1) | PL3395814T3 (OSRAM) |
| PT (1) | PT3395814T (OSRAM) |
| RS (1) | RS63405B1 (OSRAM) |
| RU (1) | RU2704112C2 (OSRAM) |
| SI (1) | SI3395814T1 (OSRAM) |
| SM (1) | SMT202200292T1 (OSRAM) |
| TW (1) | TWI675828B (OSRAM) |
| UY (1) | UY35798A (OSRAM) |
| WO (1) | WO2015061572A1 (OSRAM) |
| ZA (1) | ZA201601971B (OSRAM) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| ES2984771T3 (es) | 2012-06-13 | 2024-10-31 | Incyte Holdings Corp | Compuestos tricíclicos sustituidos como inhibidores de FGFR |
| RU2019102203A (ru) * | 2012-07-11 | 2019-03-05 | Блюпринт Медсинс Корпорейшн | Ингибиторы рецептора фактора роста фибробластов |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| KR102350704B1 (ko) | 2013-03-15 | 2022-01-13 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| CN111793068A (zh) | 2013-03-15 | 2020-10-20 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| WO2015057873A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| AR098048A1 (es) | 2013-10-18 | 2016-04-27 | Eisai R&D Man Co Ltd | Inhibidores de fgfr4 |
| TR201810944T4 (tr) | 2013-10-25 | 2018-08-27 | Novartis Ag | Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri. |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| WO2016015597A1 (en) | 2014-07-26 | 2016-02-04 | Sunshine Lake Pharma Co., Ltd. | Compounds as cdk small-molecule inhibitors and uses thereof |
| ES2756748T3 (es) | 2014-10-03 | 2020-04-27 | Novartis Ag | Uso de derivados de piridilo bicíclicos de anillo fusionado como inhibidores de fgfr4 |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| JP6431622B2 (ja) | 2015-04-14 | 2018-11-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 結晶性ｆｇｆｒ４阻害剤化合物およびその使用 |
| EP3322706B1 (en) | 2015-07-16 | 2020-11-11 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
| AU2016297754A1 (en) | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| TWI757256B (zh) | 2015-11-02 | 2022-03-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
| EP3377497A1 (en) | 2015-11-19 | 2018-09-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| HUE068971T2 (hu) | 2016-04-04 | 2025-02-28 | Loxo Oncology Inc | (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| RS65988B1 (sr) | 2016-04-04 | 2024-10-31 | Loxo Oncology Inc | Postupak lečenja pedijatrijskih karcinoma |
| EP3442977B1 (en) | 2016-04-15 | 2023-06-28 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| US11357769B2 (en) | 2016-05-10 | 2022-06-14 | Eisai R&D Management Co., Ltd. | Drug combinations for reducing cell viability and/or cell proliferation |
| SI3458456T1 (sl) | 2016-05-18 | 2021-04-30 | Loxo Oncology, Inc. | Priprava (S)-N-(5-((R)-2-(2,5-difluorofenil) pirolidin-1-il) pirazolo (1,5-A) pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| RU2732127C1 (ru) * | 2016-09-01 | 2020-09-11 | Наньцзин Транстера Биосайенсиз Ко. Лтд. | Ингибиторы рецептора фактора роста фибробластов и их применение |
| US20190192522A1 (en) * | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CN106986809B (zh) * | 2016-12-02 | 2020-03-24 | 广东省微生物研究所（广东省微生物分析检测中心） | 一种5-溴-6-氯-3-吲哚辛酯的合成方法 |
| RU2747260C2 (ru) | 2016-12-19 | 2021-04-29 | Аббиско Тхерапеутицс Цо., Лтд. | Ингибитор рфрф4, способ его получения и его фармацевтическое применение |
| CN108264511B (zh) * | 2017-01-03 | 2021-04-13 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和其在医药上的用途 |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CN108503593B (zh) * | 2017-02-28 | 2021-04-27 | 暨南大学 | 2-氨基嘧啶类化合物及其应用 |
| WO2018160076A1 (en) * | 2017-03-03 | 2018-09-07 | Auckland Uniservices Limited | Fgfr kinase inhibitors and pharmaceutical uses |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CN108689878B (zh) * | 2017-04-10 | 2023-05-09 | 浙江九洲药业股份有限公司 | 光学活性二氨基衍生物的制备方法 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| JP7346420B2 (ja) * | 2017-09-05 | 2023-09-19 | バイオアーディス エルエルシー | 芳香族誘導体、その調製方法、およびその医学的適用 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| US11236086B2 (en) | 2017-10-18 | 2022-02-01 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
| EP3712146A4 (en) * | 2017-11-01 | 2021-05-05 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | SALT FORM AND CRYSTALLINE FORM OF A COMPOUND USED AS AN FGFR4 INHIBITOR AND RELATED PREPARATION PROCESS |
| CN109745325B (zh) * | 2017-11-08 | 2022-02-15 | 上海翰森生物医药科技有限公司 | Fgfr4抑制剂、其制备方法和用途 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| TW201938169A (zh) | 2018-01-18 | 2019-10-01 | 美商亞雷生物製藥股份有限公司 | 作為RET激酶抑制劑之經取代吡唑并[3,4-d]嘧啶化合物 |
| JP7422084B2 (ja) | 2018-04-03 | 2024-01-25 | ブループリント メディシンズ コーポレイション | Ｒｅｔ変化を有する癌の処置において使用するためのｒｅｔ阻害剤 |
| US11174257B2 (en) | 2018-05-04 | 2021-11-16 | Incyte Corporation | Salts of an FGFR inhibitor |
| RS66310B1 (sr) | 2018-05-04 | 2025-01-31 | Incyte Corp | Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu |
| CN111868058B (zh) * | 2018-05-25 | 2023-06-13 | 上海和誉生物医药科技有限公司 | 一种fgfr抑制剂、其制备方法和在药学上的应用 |
| KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
| ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
| SG11202103092VA (en) | 2018-09-27 | 2021-04-29 | Betta Pharmaceuticals Co Ltd | Fgfr4 inhibitor and use thereof |
| CN110950867A (zh) * | 2018-09-27 | 2020-04-03 | 首药控股(北京)有限公司 | 一种fgfr4激酶抑制剂及其制备方法和用途 |
| CN111138459B (zh) * | 2018-11-06 | 2022-10-18 | 南京圣和药业股份有限公司 | Fgfr4抑制剂的光学异构体及其应用 |
| WO2020119606A1 (en) * | 2018-12-10 | 2020-06-18 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of fibroblast growth factor receptor |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| WO2020177067A1 (en) | 2019-03-05 | 2020-09-10 | Bioardis Llc | Aromatic derivatives, preparation methods, and medical uses thereof |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| SMT202300447T1 (it) | 2019-04-12 | 2024-01-10 | Blueprint Medicines Corp | Forme cristalline di (s)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1h-pirazol-4-yl)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-ammina e metodi di produzione |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| ES3007814T3 (en) | 2019-08-08 | 2025-03-20 | Zhangzhou Pien Tze Huang Pharm | Pyrazine-2(1h)-ketone compound preparation method |
| ES2954774T3 (es) * | 2019-08-08 | 2023-11-24 | Zhangzhou Pien Tze Huang Pharm | Forma cristalina A y forma cristalina B del compuesto de pirazina-2(1H)-cetona y su método de preparación |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| PH12022550892A1 (en) | 2019-10-14 | 2023-05-03 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CN112759593A (zh) | 2019-11-01 | 2021-05-07 | 北京伯汇生物技术有限公司 | 桥环并醛基吡啶衍生物及其应用 |
| CN114728058A (zh) * | 2019-11-04 | 2022-07-08 | 基石药业（苏州）有限公司 | Fgfr4/pd-1组合治疗 |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| WO2021113492A1 (en) | 2019-12-06 | 2021-06-10 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| CN113087696A (zh) * | 2019-12-23 | 2021-07-09 | 江苏开元药业有限公司 | 喹啉类化合物及其应用 |
| MX2022007171A (es) | 2019-12-27 | 2022-08-22 | Schroedinger Inc | Compuestos cíclicos y métodos de uso de estos. |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202144354A (zh) | 2020-03-27 | 2021-12-01 | 大陸商貝達藥業股份有限公司 | Fgfr4抑制劑的鹽型、晶型及其用途 |
| CA3183728A1 (en) | 2020-05-29 | 2021-12-02 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| EP4211140A1 (en) | 2020-09-10 | 2023-07-19 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
| WO2022058838A1 (ja) * | 2020-09-18 | 2022-03-24 | 株式会社半導体エネルギー研究所 | 半導体装置、および電子機器 |
| MX2023003245A (es) | 2020-09-18 | 2023-04-11 | Sumitomo Pharma Co Ltd | Derivados de amina novedosos. |
| AU2021355919A1 (en) | 2020-10-05 | 2023-05-11 | Chiome Bioscience Inc. | Medicine for treating cancer |
| EP4284804A1 (en) | 2021-01-26 | 2023-12-06 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| WO2022194160A1 (zh) * | 2021-03-16 | 2022-09-22 | 上海启晟合研医药科技有限公司 | 非索替尼固体形式及其制备方法 |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| MX2023011342A (es) * | 2021-03-26 | 2023-10-04 | Hangzhou Apeloa Medicine Res Institute Co Ltd | Inhibidor heterociclico biciclico de fgfr4, su composicion farmaceutica y formulacion, y sus aplicaciones. |
| JP2024513575A (ja) | 2021-04-12 | 2024-03-26 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法 |
| WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313610A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| TWI896159B (zh) * | 2023-06-09 | 2025-09-01 | 大陸商上海和譽生物醫藥科技有限公司 | 一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用 |
| WO2025059027A1 (en) | 2023-09-11 | 2025-03-20 | Schrödinger, Inc. | Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors |
| CN118221569A (zh) * | 2024-03-22 | 2024-06-21 | 浙江大学 | 一种环戊烷-1,2-二胺衍生物及其制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2146782T3 (es) | 1994-11-14 | 2000-08-16 | Warner Lambert Co | 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa. |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| GB9708917D0 (en) | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| CN1138778C (zh) | 1998-05-26 | 2004-02-18 | 沃尼尔·朗伯公司 | 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途 |
| US6403799B1 (en) | 1999-10-21 | 2002-06-11 | Agouron Pharmaceuticals, Inc. | Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors |
| ATE353329T1 (de) | 1999-10-21 | 2007-02-15 | Hoffmann La Roche | Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen |
| AU1462101A (en) | 1999-11-22 | 2001-06-04 | Warner-Lambert Company | Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| US6605615B2 (en) | 2000-03-01 | 2003-08-12 | Tularik Inc. | Hydrazones and analogs as cholesterol lowering agents |
| JP2004519422A (ja) | 2000-08-04 | 2004-07-02 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン |
| US6653313B2 (en) | 2000-08-10 | 2003-11-25 | Warner-Lambert Company Llc | 1,4-dihydropyridine compounds as bradykinin antagonists |
| WO2002076985A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| GEP20063909B (en) | 2002-01-22 | 2006-08-25 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES |
| WO2004063195A1 (en) * | 2003-01-03 | 2004-07-29 | Sloan-Kettering Institute For Cancer Research | Pyridopyrimidine kinase inhibitors |
| US20050124562A1 (en) | 2003-09-23 | 2005-06-09 | Joseph Guiles | Bis-quinazoline compounds for the treatment of bacterial infections |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| CN101107248A (zh) | 2005-01-28 | 2008-01-16 | 埃科特莱茵药品有限公司 | 作为用于治疗高血压的肾素抑制剂的7－{4－[2－(2,6－二氯－4－甲基苯氧基)乙氧基]苯基}－3,9－二氮杂双环[3.3.1]壬－6－烯－6－羧酸环丙基－(2,3－二甲基苄基)酰胺 |
| JP5079500B2 (ja) | 2005-04-28 | 2012-11-21 | 協和発酵キリン株式会社 | ２−アミノキナゾリン誘導体 |
| HRP20150642T1 (hr) | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
| US20100216767A1 (en) | 2006-12-22 | 2010-08-26 | Mina Aikawa | Quinazolines for pdk1 inhibition |
| GB2467670B (en) | 2007-10-04 | 2012-08-01 | Intellikine Inc | Chemical entities and therapeutic uses thereof |
| TWI458721B (zh) | 2008-06-27 | 2014-11-01 | Celgene Avilomics Res Inc | 雜芳基化合物及其用途 |
| CN102224170A (zh) | 2008-09-03 | 2011-10-19 | 利琴蒂亚有限公司 | 抑制与fgfr4相关的癌细胞侵袭的材料和方法 |
| CN102405284B (zh) * | 2008-09-05 | 2016-01-20 | 新基阿维罗米克斯研究公司 | 设计不可逆抑制剂的算法 |
| PE20120424A1 (es) | 2008-12-29 | 2012-05-04 | Fovea Pharmaceuticals | Compuestos de quinazolina sustituidos |
| KR101529767B1 (ko) | 2009-08-07 | 2015-06-17 | 추가이 세이야쿠 가부시키가이샤 | 아미노피라졸 유도체 |
| EP2478361A4 (en) | 2009-09-16 | 2014-05-21 | Celgene Avilomics Res Inc | CONJUGATES AND INHIBITORS OF PROTEIN KINASE |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| MX340408B (es) | 2011-04-21 | 2016-07-07 | Ionis Pharmaceuticals Inc | Modulacion de la expresion del virus de hepatitis b (vhb). |
| ES2770550T3 (es) | 2011-05-17 | 2020-07-02 | Univ California | Inhibidores de quinasa |
| FR2985257B1 (fr) | 2011-12-28 | 2014-02-14 | Sanofi Sa | Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique |
| AU2013210403B2 (en) | 2012-01-19 | 2016-01-14 | Taiho Pharmaceutical Co., Ltd. | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| RU2019102203A (ru) | 2012-07-11 | 2019-03-05 | Блюпринт Медсинс Корпорейшн | Ингибиторы рецептора фактора роста фибробластов |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| WO2014044846A1 (en) | 2012-09-24 | 2014-03-27 | Evotec (Uk) Ltd. | 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| HUE040434T2 (hu) | 2013-02-21 | 2019-03-28 | Pfizer | Szelektív CDK4/6 inhibitor szilárd alakjai |
| US9499522B2 (en) | 2013-03-15 | 2016-11-22 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CN111793068A (zh) * | 2013-03-15 | 2020-10-20 | 西建卡尔有限责任公司 | 杂芳基化合物和其用途 |
| TWI647220B (zh) | 2013-03-15 | 2019-01-11 | 美商西建卡爾有限責任公司 | 雜芳基化合物及其用途 |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| WO2015057873A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| AR098048A1 (es) | 2013-10-18 | 2016-04-27 | Eisai R&D Man Co Ltd | Inhibidores de fgfr4 |
| TR201810944T4 (tr) | 2013-10-25 | 2018-08-27 | Novartis Ag | Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri. |
| PT3395814T (pt) | 2013-10-25 | 2022-07-27 | Blueprint Medicines Corp | Inibidores do recetor do fator de crescimento de fibroblastos |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| US9715813B1 (en) | 2014-03-02 | 2017-07-25 | Durex International Corp | Visibility electronic controller and current-based status monitor |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| US20160115164A1 (en) | 2014-10-22 | 2016-04-28 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| AU2016297754A1 (en) | 2015-07-24 | 2018-02-15 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to KIT and PDGFR |
| AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| CA3002560A1 (en) | 2015-10-23 | 2017-04-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases |
| TWI757256B (zh) | 2015-11-02 | 2022-03-11 | 美商纜圖藥品公司 | 轉染過程重排之抑制劑 |
| EP3377497A1 (en) | 2015-11-19 | 2018-09-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| EP3442977B1 (en) | 2016-04-15 | 2023-06-28 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| US20190192522A1 (en) | 2016-09-08 | 2019-06-27 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor 4 in combination with cyclin-dependent kinase inhibitors |
-
2014
- 2014-10-23 PT PT181771312T patent/PT3395814T/pt unknown
- 2014-10-23 US US14/521,909 patent/US9434700B2/en active Active
- 2014-10-23 CA CA2928042A patent/CA2928042C/en active Active
- 2014-10-23 KR KR1020167012396A patent/KR102405452B1/ko active Active
- 2014-10-23 EP EP14802532.3A patent/EP3060560A1/en not_active Withdrawn
- 2014-10-23 AU AU2014339972A patent/AU2014339972B9/en active Active
- 2014-10-23 SI SI201431968T patent/SI3395814T1/sl unknown
- 2014-10-23 SM SM20220292T patent/SMT202200292T1/it unknown
- 2014-10-23 EP EP18177131.2A patent/EP3395814B1/en active Active
- 2014-10-23 JP JP2016525063A patent/JP6458023B2/ja active Active
- 2014-10-23 RS RS20220624A patent/RS63405B1/sr unknown
- 2014-10-23 HU HUE18177131A patent/HUE059037T2/hu unknown
- 2014-10-23 DK DK18177131.2T patent/DK3395814T3/da active
- 2014-10-23 BR BR112016008849A patent/BR112016008849B8/pt active IP Right Grant
- 2014-10-23 LT LTEP18177131.2T patent/LT3395814T/lt unknown
- 2014-10-23 ES ES18177131T patent/ES2924111T3/es active Active
- 2014-10-23 RU RU2016120012A patent/RU2704112C2/ru active
- 2014-10-23 CN CN201910274804.3A patent/CN110028491B/zh active Active
- 2014-10-23 WO PCT/US2014/061974 patent/WO2015061572A1/en not_active Ceased
- 2014-10-23 PH PH1/2016/500739A patent/PH12016500739B1/en unknown
- 2014-10-23 HR HRP20220840TT patent/HRP20220840T1/hr unknown
- 2014-10-23 PL PL18177131.2T patent/PL3395814T3/pl unknown
- 2014-10-23 MX MX2016005297A patent/MX2016005297A/es active IP Right Grant
- 2014-10-23 CN CN201480058647.8A patent/CN105658642B/zh active Active
- 2014-10-24 TW TW103136870A patent/TWI675828B/zh active
- 2014-10-24 UY UY0001035798A patent/UY35798A/es unknown
-
2016
- 2016-03-22 ZA ZA2016/01971A patent/ZA201601971B/en unknown
- 2016-03-23 IL IL244738A patent/IL244738B/en unknown
- 2016-07-28 US US15/222,523 patent/US10221154B2/en active Active
-
2018
- 2018-10-01 JP JP2018186710A patent/JP2019019131A/ja active Pending
-
2019
- 2019-02-19 US US16/279,904 patent/US10875837B2/en active Active
-
2020
- 2020-11-24 US US17/102,628 patent/US20210347756A1/en not_active Abandoned
-
2022
- 2022-07-05 CY CY20221100453T patent/CY1125393T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016500739A1 (en) | Inhibitors of the fibrolast growth factor receptor | |
| MX2020005181A (es) | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| PH12017500509A1 (en) | Benzyl substituted indazoles as bub1 inhibitors | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
| PH12017500408B1 (en) | Heteroaryl compounds as btk inhibitors and uses thereof | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| SG10201902326XA (en) | Mk2 inhibitors and uses thereof | |
| PH12016500330B1 (en) | Certain chemical entities, compositions, and methods | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| MX2021001231A (es) | Compuestos heterociclicos y sus usos. | |
| MX2020004205A (es) | Composiciones antibioticas de ceftolozano. | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| EP3046554A4 (en) | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | |
| PH12016500347A1 (en) | Triazolopyridine compounds, compositions and methods of use thereof | |
| IN2014CN04050A (OSRAM) | ||
| PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| SG10201900598TA (en) | Factor viii formulation | |
| MX363631B (es) | Composiciones y metodos para tratar infecciones bacterianas. | |
| MX2015013021A (es) | 5-bromo-indirrubinas. | |
| EA201691493A1 (ru) | Замещенные n-арилпиридиноны | |
| MX2016004573A (es) | Inhibidores de nsp4 y metodos de uso. | |
| MY180947A (en) | Ceftolozane antibiotic compositions | |
| MY182434A (en) | Certain chemical entities, compositions, and methods |